However, a relatively novel topic of research that is still in its early phases indicates that chemokines can impact immune activities not only by directly dictating the leukocyte landscape at tumor/metastatic sites but also by affecting aspects related to inhibitory immune checkpoints—such as the PD-1/PD-L1 axis—and their blockade. This evidence concerns the gene CD274 and neoplasm.